Oxford Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Oxford Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-46,041	Closed	-$398K	–	1428
2019 Q4	$398K	Buy	+46,041	New	+$258K	0.01%	1335
2019 Q2	–	Sell	-10,929	Closed	-$183K	–	2014
2019 Q1	$183K	Sell	10,929 -41,063	-79%	-$591K	﹤0.01%	1522
2018 Q4	$597K	Buy	+51,992	New	+$1.05M	0.02%	1116
2018 Q1	–	Sell	-33,014	Closed	-$1.12M	–	1939
2017 Q4	$1.12M	Buy	+33,014	New	+$890K	0.02%	881

Other funds holding MRNS

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Oxford Asset Management's MRNS Position: Q1 2020 in Review

Oxford Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2020, closing a stake of 46,041 shares — an estimated $398K sold.

Oxford Asset Management first reported a position in MRNS in Q4 2017 and held it in 4 quarters. The position peaked at $1.12M in Q4 2017. 74 funds tracked by Wall St. Rank hold MRNS as of Q1 2020.

Oxford Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 46,041 Marinus Pharmaceuticals, Inc shares in Q1 2020, an estimated $398K.
Oxford Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 4 quarters.
Oxford Asset Management's Marinus Pharmaceuticals, Inc position peaked at $1.12M in Q4 2017.
74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.